Applied Nutrition sales rise as cash conversion falls

Applied Nutrition sales rise as cash conversion falls

Applied Nutrition reports higher sales alongside weaker cash conversion figures. Revenue increased 50.9% to £161.6m, but investment in stock, manufacturing capacity, and international expansion reduced free cash flow.


Applied Nutrition has reported a 50.9% increase in annual revenue to £161.6m, supported by international expansion and new products, although higher inventory requirements and manufacturing investment have reduced the amount of cash generated by the business.

The Liverpool-based Applied Nutrition recorded revenue of £107.1m in the previous financial year, with its unaudited preliminary results showing growth across each of its principal geographical markets during the 12 months ended 31 July 2026.

Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 40.1% to £43.3m, compared with £30.9m a year earlier.

Statutory pre-tax profit rose 43.9% to £41m, while adjusted pre-tax profit increased 39.1% to £42m.

The company’s gross profit reached £71.3m, an increase of 44.6%, although gross profit grew more slowly than revenue as the business expanded.

Most of the sales growth came from existing operations. The acquisition of US sports nutrition manufacturer Nutrablend contributed £1.6m of revenue following completion in June, leaving organic growth of 49.4%.

UK revenue increased 45.2% to £70.3m, while European sales rose 34% to £20.9m.

Revenue from the rest of the world reached £70.4m, an increase of 63.3%, reflecting higher international demand and the continued development of distribution arrangements.

The company’s second-half revenue reached approximately £87.1m, compared with £59.5m during the equivalent period a year earlier.

Expansion increases working capital requirements —

The stronger sales performance has coincided with substantial investment in manufacturing capacity, inventory, and international operations.

Applied Nutrition acquired the trade and most of the assets of Nutrablend in Buffalo, New York, establishing a manufacturing base intended to support its expansion in the US market.

The group has also begun construction of an extension to its UK production facilities, alongside a new global distribution centre and head office.

When completed, the expanded British facilities are expected to support production capacity equivalent to approximately £300m in annual revenue.

That figure represents the company’s anticipated manufacturing capacity rather than a sales forecast or confirmed future revenue.

Product development has supported expansion into additional retail categories. During the year, Applied Nutrition launched a collaboration with SLUSH PUPPiE and agreed licensing arrangements involving SOUR PATCH KIDS and SWEDISH FISH.

However, increasing sales and manufacturing activity has required more cash to be committed to the business.

Inventories rose from £22.8m to £44.5m, while trade and other receivables increased from £27.4m to £42.8m.

Free cash flow after tax declined 35.8% to £10.6m, from £16.5m in the preceding year.

The conversion of adjusted after-tax profit into free cash flow fell from 72.4% to 33.5%, demonstrating how the company’s operating expansion has affected cash generation despite rising earnings.

Applied Nutrition ended the financial year with net cash of £15.9m, excluding lease liabilities, after funding the US acquisition and additional investment in stock and facilities.

The group also maintains a £30m revolving credit facility to provide financial flexibility for operations and potential acquisitions.

Management has maintained its expectations for the financial year ending July 2027, forecasting revenue of approximately £205m and adjusted EBITDA of around £49m.

Those expectations imply further revenue growth but a slightly lower adjusted EBITDA margin, reflecting the anticipated contribution from lower-margin US operations and higher whey protein costs.

The company has introduced price increases to offset some of those input costs, although it expects average whey protein prices to remain above the previous year’s level.

No dividend was declared for FY2026, and the board does not currently expect to declare another before FY2028, prioritising investment in capacity, operational efficiency, and potential acquisitions.

Applied Nutrition said trading momentum had continued into the first quarter of its new financial year. Its preliminary results show revenue and earnings growth alongside substantially higher working capital requirements as the company expands its manufacturing and international operations.

—



  • MHA plans UK rebrand as Baker Tilly

    MHA plans UK rebrand as Baker Tilly

    MHA plans to adopt the Baker Tilly brand next February. The conditional UK rebrand will align its identity with an international professional services network while retaining its existing strategy.


  • Applied Nutrition sales rise as cash conversion falls

    Applied Nutrition sales rise as cash conversion falls

    Applied Nutrition reports higher sales alongside weaker cash conversion figures. Revenue increased 50.9% to £161.6m, but investment in stock, manufacturing capacity, and international expansion reduced free cash flow.


  • Imperial secures £1.8m for manufacturing AI

    Imperial secures £1.8m for manufacturing AI

    Imperial researchers have secured funding to develop trustworthy manufacturing AI. The £1.8m project will help engineers evaluate component designs and identify when automated predictions require additional verification.